nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—MAPK8—brown adipose tissue—metabolic syndrome X	0.028	0.0779	CbGeAlD
Nilotinib—CA3—pericardium—metabolic syndrome X	0.02	0.0556	CbGeAlD
Nilotinib—PDGFRA—penis—metabolic syndrome X	0.0139	0.0387	CbGeAlD
Nilotinib—MAPK8—artery—metabolic syndrome X	0.0123	0.0343	CbGeAlD
Nilotinib—MAPK8—endothelium—metabolic syndrome X	0.0104	0.029	CbGeAlD
Nilotinib—MAPK8—blood vessel—metabolic syndrome X	0.00962	0.0267	CbGeAlD
Nilotinib—TIE1—endothelium—metabolic syndrome X	0.00904	0.0251	CbGeAlD
Nilotinib—TIE1—blood vessel—metabolic syndrome X	0.00834	0.0232	CbGeAlD
Nilotinib—TEK—artery—metabolic syndrome X	0.00711	0.0198	CbGeAlD
Nilotinib—EPHB4—endothelium—metabolic syndrome X	0.00628	0.0175	CbGeAlD
Nilotinib—MAPK14—blood vessel—metabolic syndrome X	0.00611	0.017	CbGeAlD
Nilotinib—TEK—endothelium—metabolic syndrome X	0.00601	0.0167	CbGeAlD
Nilotinib—EPHB4—blood vessel—metabolic syndrome X	0.00579	0.0161	CbGeAlD
Nilotinib—EPHA2—blood vessel—metabolic syndrome X	0.00568	0.0158	CbGeAlD
Nilotinib—TEK—blood vessel—metabolic syndrome X	0.00554	0.0154	CbGeAlD
Nilotinib—CDC42BPB—cardiovascular system—metabolic syndrome X	0.00474	0.0132	CbGeAlD
Nilotinib—KIT—endothelium—metabolic syndrome X	0.00435	0.0121	CbGeAlD
Nilotinib—MAPK8—cardiovascular system—metabolic syndrome X	0.00429	0.0119	CbGeAlD
Nilotinib—MAPK11—adipose tissue—metabolic syndrome X	0.00422	0.0117	CbGeAlD
Nilotinib—MAPK8—kidney—metabolic syndrome X	0.0042	0.0117	CbGeAlD
Nilotinib—CDC42BPB—adipose tissue—metabolic syndrome X	0.00418	0.0116	CbGeAlD
Nilotinib—KIT—blood vessel—metabolic syndrome X	0.00401	0.0112	CbGeAlD
Nilotinib—EPHA3—adipose tissue—metabolic syndrome X	0.00397	0.011	CbGeAlD
Nilotinib—PDGFRB—blood vessel—metabolic syndrome X	0.00392	0.0109	CbGeAlD
Nilotinib—Contusion—Metformin—metabolic syndrome X	0.00391	0.0309	CcSEcCtD
Nilotinib—Chest discomfort—Metformin—metabolic syndrome X	0.00386	0.0305	CcSEcCtD
Nilotinib—MAPK8—adipose tissue—metabolic syndrome X	0.00378	0.0105	CbGeAlD
Nilotinib—TIE1—cardiovascular system—metabolic syndrome X	0.00372	0.0103	CbGeAlD
Nilotinib—FRK—liver—metabolic syndrome X	0.00348	0.00967	CbGeAlD
Nilotinib—MAP4K1—adipose tissue—metabolic syndrome X	0.00344	0.00956	CbGeAlD
Nilotinib—TIE1—adipose tissue—metabolic syndrome X	0.00328	0.00912	CbGeAlD
Nilotinib—BRAF—adipose tissue—metabolic syndrome X	0.00315	0.00874	CbGeAlD
Nilotinib—CA7—kidney—metabolic syndrome X	0.00311	0.00865	CbGeAlD
Nilotinib—CDC42BPB—liver—metabolic syndrome X	0.00293	0.00816	CbGeAlD
Nilotinib—CA3—cardiovascular system—metabolic syndrome X	0.00292	0.00811	CbGeAlD
Nilotinib—Ear pain—Metformin—metabolic syndrome X	0.0029	0.023	CcSEcCtD
Nilotinib—HCK—adipose tissue—metabolic syndrome X	0.00287	0.00797	CbGeAlD
Nilotinib—ABL2—adipose tissue—metabolic syndrome X	0.00285	0.00792	CbGeAlD
Nilotinib—MAPK14—cardiovascular system—metabolic syndrome X	0.00273	0.00757	CbGeAlD
Nilotinib—FGR—cardiovascular system—metabolic syndrome X	0.00271	0.00754	CbGeAlD
Nilotinib—MAPK14—kidney—metabolic syndrome X	0.00267	0.00741	CbGeAlD
Nilotinib—MAPK8—liver—metabolic syndrome X	0.00265	0.00738	CbGeAlD
Nilotinib—EPHA4—adipose tissue—metabolic syndrome X	0.00261	0.00724	CbGeAlD
Nilotinib—EPHB4—cardiovascular system—metabolic syndrome X	0.00258	0.00718	CbGeAlD
Nilotinib—CA3—adipose tissue—metabolic syndrome X	0.00257	0.00715	CbGeAlD
Nilotinib—Hypoglycaemia—Metformin—metabolic syndrome X	0.00254	0.0201	CcSEcCtD
Nilotinib—EPHA2—cardiovascular system—metabolic syndrome X	0.00253	0.00704	CbGeAlD
Nilotinib—Lethargy—Metformin—metabolic syndrome X	0.00253	0.02	CcSEcCtD
Nilotinib—EPHB4—kidney—metabolic syndrome X	0.00253	0.00703	CbGeAlD
Nilotinib—Pain in extremity—Metformin—metabolic syndrome X	0.00248	0.0196	CcSEcCtD
Nilotinib—TEK—cardiovascular system—metabolic syndrome X	0.00247	0.00687	CbGeAlD
Nilotinib—LYN—liver—metabolic syndrome X	0.00245	0.00681	CbGeAlD
Nilotinib—Migraine—Metformin—metabolic syndrome X	0.00244	0.0193	CcSEcCtD
Nilotinib—TEK—kidney—metabolic syndrome X	0.00242	0.00672	CbGeAlD
Nilotinib—MAPK14—adipose tissue—metabolic syndrome X	0.0024	0.00668	CbGeAlD
Nilotinib—FGR—adipose tissue—metabolic syndrome X	0.00239	0.00665	CbGeAlD
Nilotinib—LCK—adipose tissue—metabolic syndrome X	0.00239	0.00665	CbGeAlD
Nilotinib—Dehydration—Metformin—metabolic syndrome X	0.0023	0.0182	CcSEcCtD
Nilotinib—TIE1—liver—metabolic syndrome X	0.0023	0.00639	CbGeAlD
Nilotinib—EPHB4—adipose tissue—metabolic syndrome X	0.00228	0.00633	CbGeAlD
Nilotinib—Abdominal pain upper—Metformin—metabolic syndrome X	0.00226	0.0179	CcSEcCtD
Nilotinib—PDGFRA—cardiovascular system—metabolic syndrome X	0.00224	0.00623	CbGeAlD
Nilotinib—Breast disorder—Metformin—metabolic syndrome X	0.00224	0.0177	CcSEcCtD
Nilotinib—EPHA2—adipose tissue—metabolic syndrome X	0.00223	0.00621	CbGeAlD
Nilotinib—Nasopharyngitis—Metformin—metabolic syndrome X	0.00222	0.0175	CcSEcCtD
Nilotinib—BRAF—liver—metabolic syndrome X	0.00221	0.00613	CbGeAlD
Nilotinib—TEK—adipose tissue—metabolic syndrome X	0.00218	0.00606	CbGeAlD
Nilotinib—Abdominal distension—Metformin—metabolic syndrome X	0.00216	0.017	CcSEcCtD
Nilotinib—Influenza—Metformin—metabolic syndrome X	0.00214	0.0169	CcSEcCtD
Nilotinib—Pancreatitis—Metformin—metabolic syndrome X	0.0021	0.0166	CcSEcCtD
Nilotinib—UGT1A1—kidney—metabolic syndrome X	0.00209	0.00581	CbGeAlD
Nilotinib—Angina pectoris—Metformin—metabolic syndrome X	0.00209	0.0165	CcSEcCtD
Nilotinib—EPHB6—adipose tissue—metabolic syndrome X	0.00208	0.00579	CbGeAlD
Nilotinib—Abdominal discomfort—Metformin—metabolic syndrome X	0.00205	0.0162	CcSEcCtD
Nilotinib—CA12—kidney—metabolic syndrome X	0.00202	0.00562	CbGeAlD
Nilotinib—MAP2K5—cardiovascular system—metabolic syndrome X	0.00202	0.00562	CbGeAlD
Nilotinib—HCK—liver—metabolic syndrome X	0.00201	0.00559	CbGeAlD
Nilotinib—Neutropenia—Metformin—metabolic syndrome X	0.002	0.0158	CcSEcCtD
Nilotinib—ABL2—liver—metabolic syndrome X	0.002	0.00555	CbGeAlD
Nilotinib—Upper respiratory tract infection—Metformin—metabolic syndrome X	0.00199	0.0157	CcSEcCtD
Nilotinib—PDGFRA—adipose tissue—metabolic syndrome X	0.00198	0.00549	CbGeAlD
Nilotinib—CSF1R—cardiovascular system—metabolic syndrome X	0.00197	0.00548	CbGeAlD
Nilotinib—Infestation NOS—Metformin—metabolic syndrome X	0.00191	0.0151	CcSEcCtD
Nilotinib—Infestation—Metformin—metabolic syndrome X	0.00191	0.0151	CcSEcCtD
Nilotinib—Neuropathy peripheral—Metformin—metabolic syndrome X	0.00187	0.0148	CcSEcCtD
Nilotinib—Hepatobiliary disease—Metformin—metabolic syndrome X	0.00181	0.0143	CcSEcCtD
Nilotinib—CA3—liver—metabolic syndrome X	0.00181	0.00502	CbGeAlD
Nilotinib—KIT—cardiovascular system—metabolic syndrome X	0.00179	0.00498	CbGeAlD
Nilotinib—MAP2K5—adipose tissue—metabolic syndrome X	0.00178	0.00495	CbGeAlD
Nilotinib—KIT—kidney—metabolic syndrome X	0.00175	0.00487	CbGeAlD
Nilotinib—PDGFRB—cardiovascular system—metabolic syndrome X	0.00175	0.00486	CbGeAlD
Nilotinib—Bradycardia—Metformin—metabolic syndrome X	0.00175	0.0138	CcSEcCtD
Nilotinib—CSF1R—adipose tissue—metabolic syndrome X	0.00174	0.00483	CbGeAlD
Nilotinib—Rhinitis—Metformin—metabolic syndrome X	0.00172	0.0136	CcSEcCtD
Nilotinib—Hepatitis—Metformin—metabolic syndrome X	0.00171	0.0136	CcSEcCtD
Nilotinib—PDGFRB—kidney—metabolic syndrome X	0.00171	0.00476	CbGeAlD
Nilotinib—Hypoaesthesia—Metformin—metabolic syndrome X	0.00171	0.0135	CcSEcCtD
Nilotinib—Oedema peripheral—Metformin—metabolic syndrome X	0.00169	0.0134	CcSEcCtD
Nilotinib—MAPK14—liver—metabolic syndrome X	0.00169	0.00468	CbGeAlD
Nilotinib—Connective tissue disorder—Metformin—metabolic syndrome X	0.00168	0.0133	CcSEcCtD
Nilotinib—FGR—liver—metabolic syndrome X	0.00168	0.00466	CbGeAlD
Nilotinib—LCK—liver—metabolic syndrome X	0.00168	0.00466	CbGeAlD
Nilotinib—CA14—liver—metabolic syndrome X	0.00164	0.00456	CbGeAlD
Nilotinib—CA1—cardiovascular system—metabolic syndrome X	0.00164	0.00455	CbGeAlD
Nilotinib—CA1—kidney—metabolic syndrome X	0.0016	0.00445	CbGeAlD
Nilotinib—Eye disorder—Metformin—metabolic syndrome X	0.0016	0.0127	CcSEcCtD
Nilotinib—EPHB4—liver—metabolic syndrome X	0.0016	0.00444	CbGeAlD
Nilotinib—Flushing—Metformin—metabolic syndrome X	0.00159	0.0126	CcSEcCtD
Nilotinib—Cardiac disorder—Metformin—metabolic syndrome X	0.00159	0.0126	CcSEcCtD
Nilotinib—KIT—adipose tissue—metabolic syndrome X	0.00158	0.00439	CbGeAlD
Nilotinib—EPHA2—liver—metabolic syndrome X	0.00157	0.00436	CbGeAlD
Nilotinib—ABL1—cardiovascular system—metabolic syndrome X	0.00156	0.00433	CbGeAlD
Nilotinib—Angiopathy—Metformin—metabolic syndrome X	0.00156	0.0123	CcSEcCtD
Nilotinib—Immune system disorder—Metformin—metabolic syndrome X	0.00155	0.0122	CcSEcCtD
Nilotinib—Mediastinal disorder—Metformin—metabolic syndrome X	0.00155	0.0122	CcSEcCtD
Nilotinib—PDGFRB—adipose tissue—metabolic syndrome X	0.00154	0.00429	CbGeAlD
Nilotinib—Chills—Metformin—metabolic syndrome X	0.00154	0.0122	CcSEcCtD
Nilotinib—TEK—liver—metabolic syndrome X	0.00153	0.00425	CbGeAlD
Nilotinib—ABL1—kidney—metabolic syndrome X	0.00153	0.00424	CbGeAlD
Nilotinib—Malnutrition—Metformin—metabolic syndrome X	0.00149	0.0118	CcSEcCtD
Nilotinib—Erythema—Metformin—metabolic syndrome X	0.00149	0.0118	CcSEcCtD
Nilotinib—Flatulence—Metformin—metabolic syndrome X	0.00147	0.0116	CcSEcCtD
Nilotinib—Dysgeusia—Metformin—metabolic syndrome X	0.00146	0.0116	CcSEcCtD
Nilotinib—CA1—adipose tissue—metabolic syndrome X	0.00144	0.00401	CbGeAlD
Nilotinib—Muscle spasms—Metformin—metabolic syndrome X	0.00143	0.0113	CcSEcCtD
Nilotinib—Vision blurred—Metformin—metabolic syndrome X	0.00141	0.0111	CcSEcCtD
Nilotinib—Tremor—Metformin—metabolic syndrome X	0.0014	0.0111	CcSEcCtD
Nilotinib—PDGFRA—liver—metabolic syndrome X	0.00139	0.00385	CbGeAlD
Nilotinib—Ill-defined disorder—Metformin—metabolic syndrome X	0.00138	0.0109	CcSEcCtD
Nilotinib—ABL1—adipose tissue—metabolic syndrome X	0.00137	0.00382	CbGeAlD
Nilotinib—Malaise—Metformin—metabolic syndrome X	0.00135	0.0106	CcSEcCtD
Nilotinib—Syncope—Metformin—metabolic syndrome X	0.00134	0.0106	CcSEcCtD
Nilotinib—UGT1A1—liver—metabolic syndrome X	0.00132	0.00367	CbGeAlD
Nilotinib—Palpitations—Metformin—metabolic syndrome X	0.00132	0.0104	CcSEcCtD
Nilotinib—Loss of consciousness—Metformin—metabolic syndrome X	0.00131	0.0104	CcSEcCtD
Nilotinib—Hypertension—Metformin—metabolic syndrome X	0.00129	0.0102	CcSEcCtD
Nilotinib—CA4—cardiovascular system—metabolic syndrome X	0.00128	0.00356	CbGeAlD
Nilotinib—Myalgia—Metformin—metabolic syndrome X	0.00127	0.01	CcSEcCtD
Nilotinib—Chest pain—Metformin—metabolic syndrome X	0.00127	0.01	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Metformin—metabolic syndrome X	0.00126	0.00998	CcSEcCtD
Nilotinib—Discomfort—Metformin—metabolic syndrome X	0.00126	0.00992	CcSEcCtD
Nilotinib—CA4—kidney—metabolic syndrome X	0.00125	0.00348	CbGeAlD
Nilotinib—MAP2K5—liver—metabolic syndrome X	0.00125	0.00347	CbGeAlD
Nilotinib—CSF1R—liver—metabolic syndrome X	0.00122	0.00339	CbGeAlD
Nilotinib—Oedema—Metformin—metabolic syndrome X	0.00122	0.00963	CcSEcCtD
Nilotinib—Infection—Metformin—metabolic syndrome X	0.00121	0.00957	CcSEcCtD
Nilotinib—Shock—Metformin—metabolic syndrome X	0.0012	0.00947	CcSEcCtD
Nilotinib—Nervous system disorder—Metformin—metabolic syndrome X	0.00119	0.00944	CcSEcCtD
Nilotinib—Thrombocytopenia—Metformin—metabolic syndrome X	0.00119	0.00943	CcSEcCtD
Nilotinib—Skin disorder—Metformin—metabolic syndrome X	0.00118	0.00935	CcSEcCtD
Nilotinib—Hyperhidrosis—Metformin—metabolic syndrome X	0.00118	0.00931	CcSEcCtD
Nilotinib—Anorexia—Metformin—metabolic syndrome X	0.00116	0.00918	CcSEcCtD
Nilotinib—Hypotension—Metformin—metabolic syndrome X	0.00114	0.009	CcSEcCtD
Nilotinib—CA4—adipose tissue—metabolic syndrome X	0.00113	0.00314	CbGeAlD
Nilotinib—Musculoskeletal discomfort—Metformin—metabolic syndrome X	0.00111	0.00877	CcSEcCtD
Nilotinib—KIT—liver—metabolic syndrome X	0.00111	0.00308	CbGeAlD
Nilotinib—Paraesthesia—Metformin—metabolic syndrome X	0.00109	0.00865	CcSEcCtD
Nilotinib—ABCB1—blood vessel—metabolic syndrome X	0.00109	0.00302	CbGeAlD
Nilotinib—Dyspnoea—Metformin—metabolic syndrome X	0.00109	0.00858	CcSEcCtD
Nilotinib—PDGFRB—liver—metabolic syndrome X	0.00108	0.00301	CbGeAlD
Nilotinib—Dyspepsia—Metformin—metabolic syndrome X	0.00107	0.00848	CcSEcCtD
Nilotinib—CA2—cardiovascular system—metabolic syndrome X	0.00106	0.00295	CbGeAlD
Nilotinib—Decreased appetite—Metformin—metabolic syndrome X	0.00106	0.00837	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Metformin—metabolic syndrome X	0.00105	0.00831	CcSEcCtD
Nilotinib—Fatigue—Metformin—metabolic syndrome X	0.00105	0.0083	CcSEcCtD
Nilotinib—Constipation—Metformin—metabolic syndrome X	0.00104	0.00823	CcSEcCtD
Nilotinib—CA2—kidney—metabolic syndrome X	0.00104	0.00289	CbGeAlD
Nilotinib—CA1—liver—metabolic syndrome X	0.00101	0.00281	CbGeAlD
Nilotinib—Feeling abnormal—Metformin—metabolic syndrome X	0.001	0.00794	CcSEcCtD
Nilotinib—Gastrointestinal pain—Metformin—metabolic syndrome X	0.000996	0.00787	CcSEcCtD
Nilotinib—CYP2C8—kidney—metabolic syndrome X	0.000989	0.00275	CbGeAlD
Nilotinib—Urticaria—Metformin—metabolic syndrome X	0.000968	0.00765	CcSEcCtD
Nilotinib—ABL1—liver—metabolic syndrome X	0.000964	0.00268	CbGeAlD
Nilotinib—Abdominal pain—Metformin—metabolic syndrome X	0.000963	0.00761	CcSEcCtD
Nilotinib—CA2—adipose tissue—metabolic syndrome X	0.000936	0.0026	CbGeAlD
Nilotinib—CYP2B6—cardiovascular system—metabolic syndrome X	0.000907	0.00252	CbGeAlD
Nilotinib—CYP2C9—cardiovascular system—metabolic syndrome X	0.000898	0.0025	CbGeAlD
Nilotinib—CYP2B6—kidney—metabolic syndrome X	0.000887	0.00247	CbGeAlD
Nilotinib—Asthenia—Metformin—metabolic syndrome X	0.000874	0.00691	CcSEcCtD
Nilotinib—ABCG2—adipose tissue—metabolic syndrome X	0.000867	0.00241	CbGeAlD
Nilotinib—Pruritus—Metformin—metabolic syndrome X	0.000862	0.00681	CcSEcCtD
Nilotinib—Diarrhoea—Metformin—metabolic syndrome X	0.000833	0.00659	CcSEcCtD
Nilotinib—Dizziness—Metformin—metabolic syndrome X	0.000805	0.00637	CcSEcCtD
Nilotinib—Vomiting—Metformin—metabolic syndrome X	0.000774	0.00612	CcSEcCtD
Nilotinib—Rash—Metformin—metabolic syndrome X	0.000768	0.00607	CcSEcCtD
Nilotinib—Dermatitis—Metformin—metabolic syndrome X	0.000767	0.00607	CcSEcCtD
Nilotinib—Headache—Metformin—metabolic syndrome X	0.000763	0.00603	CcSEcCtD
Nilotinib—Nausea—Metformin—metabolic syndrome X	0.000724	0.00572	CcSEcCtD
Nilotinib—CYP3A4—kidney—metabolic syndrome X	0.00067	0.00186	CbGeAlD
Nilotinib—CYP2D6—kidney—metabolic syndrome X	0.000659	0.00183	CbGeAlD
Nilotinib—CA2—liver—metabolic syndrome X	0.000656	0.00182	CbGeAlD
Nilotinib—CYP2C8—liver—metabolic syndrome X	0.000625	0.00174	CbGeAlD
Nilotinib—ABCG2—liver—metabolic syndrome X	0.000608	0.00169	CbGeAlD
Nilotinib—CYP2B6—liver—metabolic syndrome X	0.000561	0.00156	CbGeAlD
Nilotinib—CYP2C9—liver—metabolic syndrome X	0.000555	0.00154	CbGeAlD
Nilotinib—ABCB1—cardiovascular system—metabolic syndrome X	0.000485	0.00135	CbGeAlD
Nilotinib—ABCB1—kidney—metabolic syndrome X	0.000474	0.00132	CbGeAlD
Nilotinib—ABCB1—adipose tissue—metabolic syndrome X	0.000427	0.00119	CbGeAlD
Nilotinib—CYP3A4—liver—metabolic syndrome X	0.000424	0.00118	CbGeAlD
Nilotinib—CYP2D6—liver—metabolic syndrome X	0.000417	0.00116	CbGeAlD
Nilotinib—ABCB1—liver—metabolic syndrome X	0.0003	0.000833	CbGeAlD
Nilotinib—PDGFRB—Adaptive Immune System—AKT1—metabolic syndrome X	1.59e-05	3.1e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ABCA1—metabolic syndrome X	1.59e-05	3.1e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—SLC2A4—metabolic syndrome X	1.59e-05	3.1e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IRS1—metabolic syndrome X	1.59e-05	3.09e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—SERPINE1—metabolic syndrome X	1.58e-05	3.08e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—AKT1—metabolic syndrome X	1.58e-05	3.07e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—AKT1—metabolic syndrome X	1.58e-05	3.07e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—AKT1—metabolic syndrome X	1.57e-05	3.06e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—AKT1—metabolic syndrome X	1.56e-05	3.04e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—NOS3—metabolic syndrome X	1.56e-05	3.03e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—ALB—metabolic syndrome X	1.56e-05	3.03e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—HMGCR—metabolic syndrome X	1.56e-05	3.03e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GOT2—metabolic syndrome X	1.56e-05	3.03e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—SCARB1—metabolic syndrome X	1.55e-05	3.02e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—INS—metabolic syndrome X	1.55e-05	3.02e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—APOB—metabolic syndrome X	1.55e-05	3.01e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GOT1—metabolic syndrome X	1.54e-05	3e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GGT1—metabolic syndrome X	1.54e-05	3e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—AKT1—metabolic syndrome X	1.54e-05	3e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—SCARB1—metabolic syndrome X	1.54e-05	3e-05	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—ALB—metabolic syndrome X	1.53e-05	2.97e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCL2—metabolic syndrome X	1.53e-05	2.97e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—INS—metabolic syndrome X	1.52e-05	2.96e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NOS3—metabolic syndrome X	1.51e-05	2.94e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—SREBF1—metabolic syndrome X	1.51e-05	2.94e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—TGFB1—metabolic syndrome X	1.51e-05	2.93e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PLA2G4A—metabolic syndrome X	1.5e-05	2.93e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IRS1—metabolic syndrome X	1.5e-05	2.93e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IGF1—metabolic syndrome X	1.5e-05	2.92e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—metabolic syndrome X	1.5e-05	2.92e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—SREBF1—metabolic syndrome X	1.49e-05	2.91e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCL2—metabolic syndrome X	1.49e-05	2.91e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—NOS3—metabolic syndrome X	1.49e-05	2.9e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AGT—metabolic syndrome X	1.49e-05	2.89e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—AKT1—metabolic syndrome X	1.48e-05	2.88e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—LPL—metabolic syndrome X	1.48e-05	2.87e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PPARG—metabolic syndrome X	1.47e-05	2.86e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IGF1—metabolic syndrome X	1.47e-05	2.86e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TGFB1—metabolic syndrome X	1.47e-05	2.86e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—HMGCR—metabolic syndrome X	1.47e-05	2.86e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GOT2—metabolic syndrome X	1.47e-05	2.86e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—LEP—metabolic syndrome X	1.46e-05	2.84e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—APOE—metabolic syndrome X	1.46e-05	2.84e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—HMGCR—metabolic syndrome X	1.45e-05	2.83e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GOT2—metabolic syndrome X	1.45e-05	2.83e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—G6PD—metabolic syndrome X	1.45e-05	2.82e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—IL6—metabolic syndrome X	1.44e-05	2.81e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—INS—metabolic syndrome X	1.44e-05	2.81e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—APOA1—metabolic syndrome X	1.44e-05	2.8e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—INS—metabolic syndrome X	1.44e-05	2.8e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—TGFB1—metabolic syndrome X	1.43e-05	2.77e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PTGS2—metabolic syndrome X	1.43e-05	2.77e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SERPINE1—metabolic syndrome X	1.42e-05	2.77e-05	CbGpPWpGaD
Nilotinib—CA4—Metabolism—AKT1—metabolic syndrome X	1.42e-05	2.77e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCL2—metabolic syndrome X	1.42e-05	2.76e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HDAC3—metabolic syndrome X	1.42e-05	2.76e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CD36—metabolic syndrome X	1.4e-05	2.73e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TGFB1—metabolic syndrome X	1.4e-05	2.72e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SERPINE1—metabolic syndrome X	1.39e-05	2.71e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IGF1—metabolic syndrome X	1.39e-05	2.71e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ABCA1—metabolic syndrome X	1.39e-05	2.7e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—SLC2A4—metabolic syndrome X	1.39e-05	2.7e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GCKR—metabolic syndrome X	1.38e-05	2.69e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—LPA—metabolic syndrome X	1.38e-05	2.69e-05	CbGpPWpGaD
Nilotinib—CA2—Metabolism—AKT1—metabolic syndrome X	1.36e-05	2.66e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL6—metabolic syndrome X	1.36e-05	2.65e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTGS2—metabolic syndrome X	1.36e-05	2.65e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NOS3—metabolic syndrome X	1.36e-05	2.65e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GGT1—metabolic syndrome X	1.34e-05	2.62e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GOT1—metabolic syndrome X	1.34e-05	2.62e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PLA2G6—metabolic syndrome X	1.34e-05	2.61e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—AKT1—metabolic syndrome X	1.33e-05	2.59e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NOS3—metabolic syndrome X	1.33e-05	2.59e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOA5—metabolic syndrome X	1.33e-05	2.58e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SERPINE1—metabolic syndrome X	1.32e-05	2.57e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ALB—metabolic syndrome X	1.32e-05	2.57e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—metabolic syndrome X	1.31e-05	2.55e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—APOB—metabolic syndrome X	1.31e-05	2.55e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—AKT1—metabolic syndrome X	1.31e-05	2.55e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ABCA1—metabolic syndrome X	1.31e-05	2.54e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—SLC2A4—metabolic syndrome X	1.31e-05	2.54e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PPARA—metabolic syndrome X	1.3e-05	2.54e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IRS1—metabolic syndrome X	1.3e-05	2.53e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ABCA1—metabolic syndrome X	1.3e-05	2.52e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—SLC2A4—metabolic syndrome X	1.3e-05	2.52e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—TGFB1—metabolic syndrome X	1.28e-05	2.5e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—AKT1—metabolic syndrome X	1.28e-05	2.49e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PLA2G4A—metabolic syndrome X	1.27e-05	2.48e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GGT1—metabolic syndrome X	1.27e-05	2.46e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GOT1—metabolic syndrome X	1.27e-05	2.46e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—NOS3—metabolic syndrome X	1.26e-05	2.46e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AGT—metabolic syndrome X	1.26e-05	2.46e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NOS3—metabolic syndrome X	1.26e-05	2.46e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—AKT1—metabolic syndrome X	1.26e-05	2.45e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GOT1—metabolic syndrome X	1.26e-05	2.44e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GGT1—metabolic syndrome X	1.26e-05	2.44e-05	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—AKT1—metabolic syndrome X	1.25e-05	2.43e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—LPL—metabolic syndrome X	1.25e-05	2.43e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—IL6—metabolic syndrome X	1.25e-05	2.43e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—INS—metabolic syndrome X	1.24e-05	2.42e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—APOE—metabolic syndrome X	1.24e-05	2.41e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TRIB3—metabolic syndrome X	1.23e-05	2.4e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL6—metabolic syndrome X	1.23e-05	2.39e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCL2—metabolic syndrome X	1.22e-05	2.38e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—APOA1—metabolic syndrome X	1.22e-05	2.38e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IGF1—metabolic syndrome X	1.2e-05	2.34e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CD36—metabolic syndrome X	1.19e-05	2.31e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TGFB1—metabolic syndrome X	1.17e-05	2.28e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL6—metabolic syndrome X	1.16e-05	2.26e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TGFB1—metabolic syndrome X	1.16e-05	2.26e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—metabolic syndrome X	1.16e-05	2.25e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—AKT1—metabolic syndrome X	1.15e-05	2.24e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—AKT1—metabolic syndrome X	1.15e-05	2.24e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SERPINE1—metabolic syndrome X	1.14e-05	2.23e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOB—metabolic syndrome X	1.14e-05	2.22e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—IL6—metabolic syndrome X	1.13e-05	2.21e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—AKT1—metabolic syndrome X	1.13e-05	2.21e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PLA2G4A—metabolic syndrome X	1.11e-05	2.16e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—metabolic syndrome X	1.11e-05	2.15e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NAMPT—metabolic syndrome X	1.11e-05	2.15e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PPARA—metabolic syndrome X	1.1e-05	2.15e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—LIPC—metabolic syndrome X	1.1e-05	2.14e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GCK—metabolic syndrome X	1.1e-05	2.14e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOC3—metabolic syndrome X	1.09e-05	2.13e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NOS3—metabolic syndrome X	1.09e-05	2.12e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—LPL—metabolic syndrome X	1.09e-05	2.12e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PPARG—metabolic syndrome X	1.08e-05	2.1e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOB—metabolic syndrome X	1.07e-05	2.09e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—metabolic syndrome X	1.07e-05	2.09e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—AKT1—metabolic syndrome X	1.07e-05	2.09e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AGT—metabolic syndrome X	1.07e-05	2.08e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOB—metabolic syndrome X	1.07e-05	2.07e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CETP—metabolic syndrome X	1.06e-05	2.06e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—INS—metabolic syndrome X	1.06e-05	2.06e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TGFB1—metabolic syndrome X	1.05e-05	2.05e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—metabolic syndrome X	1.05e-05	2.05e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—metabolic syndrome X	1.05e-05	2.04e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—APOE—metabolic syndrome X	1.05e-05	2.04e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—AKT1—metabolic syndrome X	1.05e-05	2.04e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PLA2G4A—metabolic syndrome X	1.05e-05	2.03e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PLA2G4A—metabolic syndrome X	1.04e-05	2.02e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—APOA1—metabolic syndrome X	1.04e-05	2.02e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CD36—metabolic syndrome X	1.03e-05	2.01e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—TGFB1—metabolic syndrome X	1.03e-05	2.01e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—metabolic syndrome X	1.03e-05	2e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—LPL—metabolic syndrome X	1.03e-05	2e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—metabolic syndrome X	1.02e-05	1.99e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AKT1—metabolic syndrome X	1.02e-05	1.99e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—LPL—metabolic syndrome X	1.02e-05	1.98e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SCARB1—metabolic syndrome X	1.02e-05	1.98e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TGFB1—metabolic syndrome X	9.98e-06	1.94e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—AKT1—metabolic syndrome X	9.91e-06	1.93e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SREBF1—metabolic syndrome X	9.86e-06	1.92e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CD36—metabolic syndrome X	9.75e-06	1.9e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—metabolic syndrome X	9.73e-06	1.89e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AKT1—metabolic syndrome X	9.7e-06	1.89e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ALB—metabolic syndrome X	9.69e-06	1.89e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—metabolic syndrome X	9.68e-06	1.88e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—AKT1—metabolic syndrome X	9.67e-06	1.88e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CD36—metabolic syndrome X	9.66e-06	1.88e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PPARA—metabolic syndrome X	9.62e-06	1.87e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HMGCR—metabolic syndrome X	9.59e-06	1.87e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GOT2—metabolic syndrome X	9.59e-06	1.87e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—AKT1—metabolic syndrome X	9.47e-06	1.84e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—AKT1—metabolic syndrome X	9.42e-06	1.83e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AGT—metabolic syndrome X	9.31e-06	1.81e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—NOS3—metabolic syndrome X	9.27e-06	1.8e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOE—metabolic syndrome X	9.12e-06	1.78e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PPARG—metabolic syndrome X	9.12e-06	1.78e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPARA—metabolic syndrome X	9.06e-06	1.76e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOA1—metabolic syndrome X	9.02e-06	1.76e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TGFB1—metabolic syndrome X	8.99e-06	1.75e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPARA—metabolic syndrome X	8.98e-06	1.75e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—AKT1—metabolic syndrome X	8.97e-06	1.75e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—INS—metabolic syndrome X	8.95e-06	1.74e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—AKT1—metabolic syndrome X	8.93e-06	1.74e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—AKT1—metabolic syndrome X	8.92e-06	1.74e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—metabolic syndrome X	8.81e-06	1.72e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TGFB1—metabolic syndrome X	8.8e-06	1.71e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AGT—metabolic syndrome X	8.78e-06	1.71e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—metabolic syndrome X	8.73e-06	1.7e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AGT—metabolic syndrome X	8.7e-06	1.69e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOE—metabolic syndrome X	8.6e-06	1.67e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ABCA1—metabolic syndrome X	8.55e-06	1.66e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC2A4—metabolic syndrome X	8.55e-06	1.66e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOE—metabolic syndrome X	8.52e-06	1.66e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOA1—metabolic syndrome X	8.5e-06	1.65e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—metabolic syndrome X	8.48e-06	1.65e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOA1—metabolic syndrome X	8.43e-06	1.64e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—metabolic syndrome X	8.41e-06	1.64e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TGFB1—metabolic syndrome X	8.35e-06	1.62e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GGT1—metabolic syndrome X	8.28e-06	1.61e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GOT1—metabolic syndrome X	8.28e-06	1.61e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ALB—metabolic syndrome X	8.2e-06	1.6e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AKT1—metabolic syndrome X	8.13e-06	1.58e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AKT1—metabolic syndrome X	8.05e-06	1.57e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PPARG—metabolic syndrome X	7.95e-06	1.55e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—metabolic syndrome X	7.95e-06	1.55e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—NOS3—metabolic syndrome X	7.85e-06	1.53e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—INS—metabolic syndrome X	7.8e-06	1.52e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—metabolic syndrome X	7.77e-06	1.51e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—AKT1—metabolic syndrome X	7.76e-06	1.51e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—metabolic syndrome X	7.52e-06	1.46e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPARG—metabolic syndrome X	7.49e-06	1.46e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPARG—metabolic syndrome X	7.42e-06	1.45e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—INS—metabolic syndrome X	7.35e-06	1.43e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AKT1—metabolic syndrome X	7.33e-06	1.43e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—INS—metabolic syndrome X	7.28e-06	1.42e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TGFB1—metabolic syndrome X	7.22e-06	1.4e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—metabolic syndrome X	7.18e-06	1.4e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—AKT1—metabolic syndrome X	7.16e-06	1.39e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ALB—metabolic syndrome X	7.15e-06	1.39e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOB—metabolic syndrome X	7.02e-06	1.37e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AKT1—metabolic syndrome X	6.94e-06	1.35e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AKT1—metabolic syndrome X	6.85e-06	1.33e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—NOS3—metabolic syndrome X	6.84e-06	1.33e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PLA2G4A—metabolic syndrome X	6.83e-06	1.33e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—metabolic syndrome X	6.78e-06	1.32e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ALB—metabolic syndrome X	6.73e-06	1.31e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—LPL—metabolic syndrome X	6.71e-06	1.31e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ALB—metabolic syndrome X	6.68e-06	1.3e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—metabolic syndrome X	6.63e-06	1.29e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—NOS3—metabolic syndrome X	6.44e-06	1.25e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—NOS3—metabolic syndrome X	6.39e-06	1.24e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CD36—metabolic syndrome X	6.37e-06	1.24e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—metabolic syndrome X	6.29e-06	1.22e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—metabolic syndrome X	6.25e-06	1.22e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AKT1—metabolic syndrome X	6.25e-06	1.22e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AKT1—metabolic syndrome X	6.12e-06	1.19e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPARA—metabolic syndrome X	5.92e-06	1.15e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—metabolic syndrome X	5.89e-06	1.15e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—metabolic syndrome X	5.84e-06	1.14e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AKT1—metabolic syndrome X	5.81e-06	1.13e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AKT1—metabolic syndrome X	5.8e-06	1.13e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AGT—metabolic syndrome X	5.74e-06	1.12e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOE—metabolic syndrome X	5.62e-06	1.09e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOA1—metabolic syndrome X	5.56e-06	1.08e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—metabolic syndrome X	5.44e-06	1.06e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT1—metabolic syndrome X	5.02e-06	9.77e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPARG—metabolic syndrome X	4.9e-06	9.53e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—INS—metabolic syndrome X	4.8e-06	9.35e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALB—metabolic syndrome X	4.4e-06	8.57e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AKT1—metabolic syndrome X	4.26e-06	8.29e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NOS3—metabolic syndrome X	4.21e-06	8.2e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—metabolic syndrome X	3.85e-06	7.5e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AKT1—metabolic syndrome X	3.61e-06	7.02e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AKT1—metabolic syndrome X	3.14e-06	6.12e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AKT1—metabolic syndrome X	2.96e-06	5.76e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AKT1—metabolic syndrome X	2.94e-06	5.71e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKT1—metabolic syndrome X	1.94e-06	3.77e-06	CbGpPWpGaD
